Good MorningThe uptrend in equities was confirmed on Friday when the broad market advanced roughly 1% to set a new all-time high. The move was driven by better-than-expected revenue and earnings as well as upwardly revised guidance from a large number of companies reporting during the week. The key takeaway is that economic conditions remain strong despite mounting concerns for inflation. While most S&P comp companies are navigating the inflationary environment successfully there are a few who aren't.
The risks for the market this week are twofold. On one hand, about 20% of the S&P 500 Index is scheduled to report earnings while on the other, we're waiting for the next policy decision from the FOMC. Along with that is a key read on inflation due on Friday that could spook the market. The PCE price index has risen hotter than expected for three months and is accelerating, another month of similar results further cloud the outlook.
Featured: How to Collect Up To $5,917/mo From Trump’s Made In USA Boom (Ad) 
|
Markets | | | After this week’s incredible recovery in the market that obliterated any bears who were caught offsides, there are several stocks breaking out to new highs that could be worth a look at this time. Breakouts are always a great way to gauge the overall level of bullishness in the market, which i... Read the Full Story |
|
From Our Partners | | Washington is running out of money…And guess where they'll look next?
When governments go broke, they take from the people.
It's happened before, and it's happening again.
The Department of Justice just admitted that cash isn't legally YOUR property. | | Get your free guide now by clicking here >> |
|
Markets | | | TThe S&P 500 (ASX: SPY) has been making new highs it seems almost every week with a performance of over 16% year-to-date (YTD) in 2021. The question on investor’s minds is how long this strong uptrend can go and where it will go Read the Full Story |
|
Politics | | | CANBERRA, Australia — AstraZeneca has backed the advice of Australia’s immunization expert body that Sydney residents should take any COVID-19 vaccine they can get.
The Australian Technical Advisory Group on Immunisation, known as ATAGI, recommended on July 13 that adults under the ag... Read the Full Story |
|
From Our Partners | Most traders guess. This system doesn’t.
Using his Momentum Indicator, one trader turned $15K into $150K in six months — stacking 20–30% daily gains. Now he’s sharing 3 stocks flashing BUY right now, plus a free report showing how to trade them. | | Claim your 3 stock picks + free momentum trading report |
|
Politics | | | Offshore energy service companies are out to find foreign-flagged ships hauling pipeline parts and other energy-related equipment from U.S. ports and delivering or installing them in U.S. waters.
The Offshore Marine Service Association has launched a ship to gather photos and videos o... Read the Full Story |
|
Markets | | | Entertainment and toy products maker JAKKS Pacific (NASDAQ: JAKK) stock is awakening and recovering as it surges through pre-COVID price levels. The licensor of popular brands like Sonic the Hedgehog, Super Mario Brothers, Apex Legends, Disney (NYSE: DIS) Frozen, Mulan, Princess, and Raya IPs is exp... Read the Full Story |
|
From Our Partners | | AI breakthroughs. Inflation shocks. Energy rotations.
The market is moving fast — and the biggest winners often start small.
At Street Ideas, we focus on small-cap companies showing early momentum — before the crowd piles in. | | “3 Under-the-Radar Stocks Triggering Early Signals” |
|
Politics | | | A shortage of jet fuel, coupled with supply chain issues and an urgent demand from firefighting aircraft, continues to cause problems at airports around the West.
In Nevada, state and federal lawmakers said they are investigating a possible shortage of jet fuel that could delay cargo ... Read the Full Story |
|
Politics | | | Like other residents of his town in Germany, Wolfgang Huste knew a flood was coming. What nobody told him, he says, was how bad it would be.
The 66-year-old antiquarian bookseller from Ahrweiler said the first serious warning to evacuate or move to higher floors of buildings close to ... Read the Full Story |
|
Tech | | | Two companies seeking to build thousands of miles of pipeline across the Midwest are promising the effort will aid rather than hinder the fight against climate change, though some environmental groups remain skeptical.
The pipelines would stretch from North Dakota to Illinois, potenti... Read the Full Story |
|
Markets | | | American Express (NYSE: AXP) Amex was among stocks helping to propel the Dow higher Friday, following a better-than-expected earnings report.
American Express, which comprises 3.23% of the price-weighted index, provides a good illustration of the rebound in business and consumer spending afte... Read the Full Story |
|
Markets | | |
Should you blindly sign up for your company's 401(k) plan? No way! Not without some serious consideration, anyway.
It's easy to assume that your employer has your best interests at heart and will "take care of you." However, that's not always the case.
Let's take a look at three signs you'... Read the Full Story |
|
The Early Bird Stock Of The Day Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. | | View Today's Stock Pick |
|
